A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 1, 2016, Pages 63-72

  Abughosh, Susan M ^a   Wang, Xin ^a   Serna, Omar ^b   Henges, Chris ^b   Masilamani, Santhi ^a   Essien, Ekere James ^a   Chung, Nancy ^a   Fleming, Marc ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Cigna HealthSpring   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG COST; FEMALE; HUMAN; HYPERTENSION; LANGUAGE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICARE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT; PATIENT COMPLIANCE; PERCEPTION; PHARMACIST; PHYSICIAN; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SEX; TELECONSULTATION; TRAFFIC AND TRANSPORT; PHARMACY; STATISTICAL MODEL; TELEPHONE; UNITED STATES;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MEDICARE; MEDICATION ADHERENCE; PHARMACEUTICAL SERVICES; PHARMACISTS; TELEPHONE; UNITED STATES;

EID: 84960354933     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.1.63     Document Type: Article

References (83)

1. Butler RJ, Davis TK, Johnson WG, Gardner HH. Effects of nonadherence with prescription drugs among older adults. Am J Manag Care. 2011;17(2):153-60.
2. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231-55.
3. Foreman KF, Stockl KM, Le LB, et al. Impact of a text messaging pilot program on patient medication adherence. Clin Ther. 2012;34(5):1084-91.
4. Van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly:problem and possible solutions. Int J Cardiol. 2008;125(2):203-08.
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
6. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540-50.
7. Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother. 2004;2(1):36-43.
8. The Henry J. Kaiser Family Foundation. The Medicare Part D Prescription Drug Benefit. October 13, 2015. Available at: http://kff.org/medicare/factsheet/ the-medicare-prescription-drug-benefit-fact-sheet/. Accessed Assessed October 13, 2015.
9. Deedwania PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation. 2011;123(24):2776-78.
10. Deedwania PC. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin. 2005;23(2):139-52.
11. Putnam W, Lawson B, Buhariwalla F, et al. Hypertension and type 2 diabetes: what family physicians can do to improve control of blood pressure- an observational study. BMC Fam Pract. 2011;12:86.
12. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-13.
13. McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can J Cardiol. 2006;22(10):855-60.
14. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161(22):2661-67.
15. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053-59.
16. Natarajan N, Putnam W, Van Aarsen K, Beverley Lawson K, Burge F. Adherence to antihypertensive medications among family practice patients with diabetes mellitus and hypertension. Can Fam Physician. 2013;59(2):e93-100.
17. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl. 1):S1-94. Available at: http://professional. diabetes.org/admin/UserFiles/0%20-%20Sean/Documents/January%20 Supplement%20Combined_Final.pdf. Accessed November 13, 2015.
18. Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm. 2006;12(8):649-55. Available at: http://amcp.org/data/ jmcp/649-655.pdf.
19. Lopez-Jaramillo P, Lopez-Lopez J, Lopez-Lopez C, Rodriguez-Alvarez MI. The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetol Metab Syndr. 2014;6(1):31.
20. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-59.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
22. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338(10):645-52.
23. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23(5):588-94.
24. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41.
25. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408-12.
26. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171(10):1189-92.
27. Kettani FZ, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-20.
28. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-605.
29. Degli Esposti L, Saragoni S, Benemei S, et al. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011;3:47-54.
30. Piette JD, Weinberger M, Kraemer FB, McPhee SJ. Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a Department of Veterans Affairs Health Care System: a randomized controlled trial. Diabetes Care. 2001;24(2):202-08.
31. Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Koliopoulus M, Cohen HW. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. Diabetes Care. 2011;34(1):2-7.
32. Wolever RQ, Dreusicke M, Fikkan J, et al. Integrative health coaching for patients with type 2 diabetes: a randomized clinical trial. Diabetes Educ. 2010;36(4):629-39.
33. Walker EA, Schechter CB, Caban A, Basch CE. Telephone intervention to promote diabetic retinopathy screening among the urban poor. Am J Prev Med. 2008;34(3):185-91.
34. Moore JM, Shartle D, Faudskar L, Matlin OS, Brennan TA. Impact of a patient-centered pharmacy program and intervention in a high-risk group. J Manag Care Pharm. 2013;19(3):228-36. Available at: http://www.amcp.org/ WorkArea/DownloadAsset.aspx?id=16313.
35. Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. J Clin Pharm Ther. 2006;31(5):409-19.
36. Brennan TA, Dollear TJ, Hu M, et al. An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. Health Aff (Millwood). 2012;31(1):120-29.
37. Odegard PS, Carpinito G, Christensen DB. Medication adherence program:adherence challenges and interventions in type 2 diabetes. J Am Pharm Assoc (2003). 2013;53(3):267-72.
38. Odegard PS, Christensen DB. MAP study: RCT of a medication adherence program for patients with type 2 diabetes. J Am Pharm Assoc (2003). 2012;52(6):753-62.
39. Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132-40.
40. Fikri-Benbrahim N, Faus MJ, Martinez-Martinez F, Sabater-Hernández D. Impact of a community pharmacists' hypertension-care service on medication adherence. The AFenPA study. Res Social Adm Pharm. 2013;9(6):797-805.
41. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-71.
42. Lau R, Stewart K, McNamara KP, et al. Evaluation of a community pharmacy-based intervention for improving patient adherence to antihypertensives:a randomised controlled trial. BMC Health Serv Res. 2010;10:34.
43. Svarstad BL, Kotchen JM, Shireman TI, et al. Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. J Am Pharm Assoc (2003). 2013;53(5):520-29.
44. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol. 2000;50(2):172-75.
45. McLean DL, McAlister FA, Johnson JA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;168(21):2355-61.
46. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc (2003). 2009;49(2):164-70.
47. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441-53.
48. Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes:a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2012;35(12):2706-17.
49. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
50. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280-88.
51. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
52. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.
53. Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31(10):2178-88; discussion 2150-51.
54. Parikh NM, Morgan RO, Kunik ME, et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011;26(7):749-57.
55. Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012;8(5):437-44.
56. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
57. Szkiladz A, Carey K, Ackerbauer K, Heelon M, Friderici J, Kopcza K. Impact of pharmacy student and resident-led discharge counseling on heart failure patients. J Pharm Pract. 2013;26(6):574-79.
58. ASHP statement on the pharmacist's role in primary care. Am J Health Syst Pharm. 1999;56(16):1665-67.
59. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing medication adherence issues. J Am Pharm Assoc (Wash). 2002;42(1):63-71; quiz 72-73.
60. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy. 1999;19(7):860-69.
61. Krousel-Wood M, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management:perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753-69.
62. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34(4):692-97.
63. Bailey GR, Barner JC, Weems JK, et al. Assessing barriers to medication adherence in underserved patients with diabetes in Texas. Diabetes Educ. 2012;38(2):271-79.
64. Okwuonu CG, Ojimadu NE, Okaka EI, Akemokwe FM. Patient-related barriers to hypertension control in a Nigerian population. Int J Gen Med. 2014;7:345-53.
65. Spinar J, Vitovec J, Soucek M, Dusek L, Pavlik T, CORD Investigators. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitr Lek. 2009;55(5):481-88.
66. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16(1):123-26.
67. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390-95.
68. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol. 1992;47(9):1102-14.
69. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol. 1991;59(2):295-304.
70. Jones H, Edwards L, Vallis TM, et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the Diabetes Stages of Change (DiSC) study. Diabetes Care. 2003;26(3):732-37.
71. Turner AP, Sloan AP, Kivlahan DR, Haselkorn JK. Telephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosis. Rehabil Psychol. 2014;59(2):136-46.
72. Miller WR, Rollnick S. Ten things that motivational interviewing is not. Behav Cogn Psychother. 2009;37(2):129-40.
73. Christie D, Channon S. The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review. Diabetes Obes Metab. 2014;16(5):381-87.
74. Gance-Cleveland B. Motivational interviewing: improving patient education. J Pediatr Health Care. 2007;21(2):81-88.
75. Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55(513):305-12.
76. Hawkins SY. Improving glycemic control in older adults using a videophone motivational diabetes self-management intervention. Res Theory Nurs Pract. 2010;24(4):217-32.
77. Ogedegbe G, Chaplin W, Schoenthaler A, et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens. 2008;21(10):1137-43.
78. Halterman JS, Szilagyi PG, Fisher SG, et al. Randomized controlled trial to improve care for urban children with asthma: results of the School-Based Asthma Therapy trial. Arch Pediatr Adolesc Med. 2011;165(3):262-68.
79. DiIorio C, McCarty F, Resnicow K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care. 2008;20(3):273-83.
80. Bailey JE, Hajjar M, Shoib B, Tang J, Ray MM, Wan JY. Risk factors associated with antihypertensive medication nonadherence in a statewide Medicaid population. Am J Med Sci. 2014;348(5):410-15.
81. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25(10):885-92.
82. Lagu T, Weiner MG, Eachus S, Tang SS, Schwartz JS, Turner BJ. Effect of patient comorbidities on filling of antihypertensive prescriptions. Am J Manag Care. 2009;15(1):24-30.
83. Garcia-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175-94.